Microtubule beta-tubulin and Deoxyribonucleic acid

The combination regimen targeting microtubule beta-tubulin and DNA is a fundamental strategy in systemic cancer chemotherapy (National Cancer Institute). Microtubule beta-tubulin is a key structural subunit of microtubules, which are essential for maintaining cell shape, intracellular transport, and the formation of the mitotic spindle during cell division (UniProt P07437). Drugs such as taxanes bind to beta-tubulin to stabilize microtubules, while vinca alkaloids prevent their polymerization, both leading to mitotic arrest and apoptosis (Jordan & Wilson, 2004, Nat Rev Cancer). DNA serves as the primary target for various cytotoxic agents, including platinum compounds and alkylators, which induce structural damage such as cross-links and strand breaks (Dasari & Bernard-Tchouala, 2014, Eur J Pharmacol). This damage inhibits DNA replication and transcription, triggering cell death pathways particularly in rapidly dividing malignant cells. By simultaneously disrupting the mitotic machinery and the integrity of the genome, these combination therapies aim to maximize anti-tumor efficacy and reduce the likelihood of drug resistance. This approach is standard of care for numerous malignancies, including non-small cell lung cancer, ovarian cancer, and breast cancer. However, the broad mechanism of action also affects healthy dividing cells, leading to common toxicities such as myelosuppression and peripheral neuropathy.

Other names

Tubulin and DNA dual targetingTaxane-Platinum combinationAntimitotic and DNA-damaging combinationMicrotubule and DNA targeting regimen

This combination regimen exerts its therapeutic effect by simultaneously disrupting two essential cellular processes: microtubule dynamics and DNA integrity. Microtubule-targeting agents (e.g., taxanes) bind to the beta-tubulin subunit to stabilize or destabilize the mitotic spindle, causing cell cycle arrest in the M phase (Jordan & Wilson, 2004, Nat Rev Cancer). Concurrently, DNA-targeting agents (e.g., platinum compounds) create covalent adducts or cross-links within the DNA structure, which stall replication forks and inhibit transcription, primarily during the S phase (Dasari & Bernard-Tchouala, 2014, Eur J Pharmacol). The dual inhibition of these pathways leads to a synergistic induction of apoptosis in cancer cells.